Correlates of immunity for pneumococcal conjugate vaccines.
about
Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.Comparison of diagnostic criteria for common variable immunodeficiency disorderSerotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D.Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young childrenDesign of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseasesMultiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Conjugate vaccines.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Strategies for eliciting HIV-1 inhibitory antibodiesProspects for a vaccine against otitis media.Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized ope10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Correlates of protection induced by vaccination.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.Complex correlates of protection after vaccination.Invasive pneumococcal infections in adult lung transplant recipients.Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines.A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea.Systems serology: profiling vaccine induced humoral immunity against HIV.Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae.Prospects from systems serology research.Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences.Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Capsular PolysaccharidesEvaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides
P2860
Q24812739-CBC84839-969E-4E66-BB87-62B3D08C91E1Q26859119-1201B5F6-049F-4CA9-B212-A1ED9466421AQ33595352-322F46F0-CB55-4B8A-B9C4-D60F2B7CF1FDQ33797264-6B8EF604-3609-4F95-8F70-2A1221FBF7BDQ33847904-454B7BD4-F44C-4DC6-981B-76C6BD5979ECQ33966586-2776B37E-79B2-4359-B574-F903769138A5Q34260869-41206169-D27C-415A-825B-9B9C8FD90003Q34291076-24AFA299-9F9F-4108-9561-BD5C50D4A0DCQ35042732-400666B2-93BB-48B5-8ABE-B6797EE7D2A8Q35623292-84FFD20B-AB75-4AC3-81F9-7C749A35AEA7Q35874108-78DFEFFB-5F38-4FEE-BE80-A97C63F8C607Q36128243-FFC84ABA-54C9-4948-A061-AB19F8F262B7Q36452155-4F6F9674-C38D-47C1-8E56-BC4B8DEB9D2FQ36600356-CE74A522-6701-4C04-B7E6-27572B3B0DFAQ36977893-C1C14B1B-7932-470A-A52B-DFF66513E189Q37622887-D210063C-4E24-4F92-9D69-901475AB227EQ37750121-AEE0FA80-4CF5-4F86-BC96-AABE3933CBC0Q37878485-D77B3492-4A7B-4810-8EE7-15369585492DQ38121956-FF2B49F8-C9CC-415E-B203-30B7DED30B2BQ38456515-7CDA3947-EB04-40EF-BB2B-BAFFBAC8E068Q40494158-BACBECA7-0113-4ACD-9851-8D9CBC684A04Q40943510-384ADA25-0E18-4847-9127-75A0A99F022EQ41879397-35F98313-9AFF-4F5F-9C75-94141A0D6DE3Q42701700-6223A778-AA84-489F-849B-A6C9911B3BE2Q47098110-50E6660A-B273-4694-A3FB-681848BDC16FQ47104983-6841D7BD-7181-44D3-A60F-03D41F1278BDQ47134798-3DE457EB-9572-456D-9A8B-E4D85CF55C96Q47346211-39363AD2-2BD6-45D1-BAE3-AB4FE74753ADQ50090256-586D0774-4854-476B-9D22-7FA2E9468A30Q55243320-5D31F90E-24A8-43B6-A664-73BEA3EA1126Q58795936-E6A95546-9CD1-4CF4-880F-A34B75DEF825Q58795940-F3CF43E1-68D3-40ED-A6D0-72385BD748A8
P2860
Correlates of immunity for pneumococcal conjugate vaccines.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Correlates of immunity for pneumococcal conjugate vaccines.
@ast
Correlates of immunity for pneumococcal conjugate vaccines.
@en
type
label
Correlates of immunity for pneumococcal conjugate vaccines.
@ast
Correlates of immunity for pneumococcal conjugate vaccines.
@en
prefLabel
Correlates of immunity for pneumococcal conjugate vaccines.
@ast
Correlates of immunity for pneumococcal conjugate vaccines.
@en
P2093
P1433
P1476
Correlates of immunity for pneumococcal conjugate vaccines.
@en
P2093
Carl E Frasch
Carolyn D Deal
David L Klein
Lucia H Lee
Lydia A Falk
P304
P356
10.1016/S0264-410X(03)00025-2
P407
P577
2003-05-01T00:00:00Z